DOE Patents title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Tin-117m-labeled stannic (Sn/sup 4 +/) chelate of diethylenetriamine pentaacetic acid (DTPA) for application in diagnosis and therapy

Abstract

The radiopharmaceutical reagents of this invention and the class of Tin-117m radiopharmaceuticals are therapeutic and diagnostic agents that incorporate gamma-emitting nuclides that localize in bone after intravenous injection in mammals (mice, rats, dogs, and rabbits). Images reflecting bone structure or function can then be obtained by a scintillation camera that detects the distribution of ionizing radiation emitted by the radioactive agent. Tin-117m-labeled chelates of stannic tin localize almost exclusively in cortical bone. Upon intravenous injection of the reagent, the preferred chelates are phosphonate compounds, preferable, PYP, MDP, EHDP, and DTPA. This class of reagents is therapeutically and diagnostically useful in skeletal scintigraphy and for the radiotherapy of bone tumors and other disorders.

Inventors:
; ;
Issue Date:
OSTI Identifier:
6965212
Application Number:
ON: DE84011272
Assignee:
Dept. of Energy
DOE Contract Number:  
AC02-76CH00016
Resource Type:
Patent
Resource Relation:
Other Information: Portions are illegible in microfiche products
Country of Publication:
United States
Language:
English
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; 38 RADIATION CHEMISTRY, RADIOCHEMISTRY, AND NUCLEAR CHEMISTRY; DTPA; LABELLING; LABELLED COMPOUNDS; CHEMICAL PREPARATION; BONE SEEKERS; ISOMERIC NUCLEI; MICE; RADIOCHEMISTRY; RADIOPHARMACEUTICALS; TIN 117; TISSUE DISTRIBUTION; AMINO ACIDS; ANIMALS; CARBOXYLIC ACIDS; CHELATING AGENTS; CHEMISTRY; DAYS LIVING RADIOISOTOPES; DISTRIBUTION; DRUGS; EVEN-ODD NUCLEI; INTERMEDIATE MASS NUCLEI; ISOMERIC TRANSITION ISOTOPES; ISOTOPES; MAMMALS; NUCLEI; ORGANIC ACIDS; ORGANIC COMPOUNDS; RADIOISOTOPES; RADIOPROTECTIVE SUBSTANCES; RODENTS; STABLE ISOTOPES; SYNTHESIS; TIN ISOTOPES; VERTEBRATES; 550601* - Medicine- Unsealed Radionuclides in Diagnostics; 400702 - Radiochemistry & Nuclear Chemistry- Properties of Radioactive Materials

Citation Formats

Srivastava, S C, Meinken, G E, and Richards, P. Tin-117m-labeled stannic (Sn/sup 4 +/) chelate of diethylenetriamine pentaacetic acid (DTPA) for application in diagnosis and therapy. United States: N. p., 1983. Web.
Srivastava, S C, Meinken, G E, & Richards, P. Tin-117m-labeled stannic (Sn/sup 4 +/) chelate of diethylenetriamine pentaacetic acid (DTPA) for application in diagnosis and therapy. United States.
Srivastava, S C, Meinken, G E, and Richards, P. Thu . "Tin-117m-labeled stannic (Sn/sup 4 +/) chelate of diethylenetriamine pentaacetic acid (DTPA) for application in diagnosis and therapy". United States.
@article{osti_6965212,
title = {Tin-117m-labeled stannic (Sn/sup 4 +/) chelate of diethylenetriamine pentaacetic acid (DTPA) for application in diagnosis and therapy},
author = {Srivastava, S C and Meinken, G E and Richards, P},
abstractNote = {The radiopharmaceutical reagents of this invention and the class of Tin-117m radiopharmaceuticals are therapeutic and diagnostic agents that incorporate gamma-emitting nuclides that localize in bone after intravenous injection in mammals (mice, rats, dogs, and rabbits). Images reflecting bone structure or function can then be obtained by a scintillation camera that detects the distribution of ionizing radiation emitted by the radioactive agent. Tin-117m-labeled chelates of stannic tin localize almost exclusively in cortical bone. Upon intravenous injection of the reagent, the preferred chelates are phosphonate compounds, preferable, PYP, MDP, EHDP, and DTPA. This class of reagents is therapeutically and diagnostically useful in skeletal scintigraphy and for the radiotherapy of bone tumors and other disorders.},
doi = {},
journal = {},
number = ,
volume = ,
place = {United States},
year = {Thu Aug 25 00:00:00 EDT 1983},
month = {Thu Aug 25 00:00:00 EDT 1983}
}

Patent:
Search for the full text at the U.S. Patent and Trademark Office Note: You will be redirected to the USPTO site, which may require a pop-up blocker to be deactivated to view the patent. If so, you will need to manually turn off your browser's pop-up blocker, typically found within the browser settings. (See DOE Patents FAQs for more information.)

Save / Share: